obesity drug eli lilly news - Search News

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea

Hosted on MSN · 8h

Lilly Obesity Drug Gets First US Approval for Sleep Apnea

Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door for broader insurance coverage of the blockbuster medicine.

The Wall Street Journal on MSN · 7h

Eli Lilly Says FDA Approves Zepbound for Obstructive Sleep Apnea in Adults With Obesity

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Novo Nordisk, obesity

Fortune on MSN · 17h

Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results from a new drug study caused investors to flee the drugmaker. The Danish producer of Ozempic,

Reuters on MSN · 18h

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Barron's on MSN · 20h

Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and Wegovy, posted disappointing clinical trial data for its experimental obesity drug CagriSema.

15h

Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

7d

Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results